Search Results for "Neuroendocrine Carcinoma Of The Breast"
Original Source: Primary neuroendocrine carcinoma of the breast: Report of a case.
Primary neuroendocrine carcinoma (NEC) of the breast appears to be a rare neoplasm. Due to the limited number of the cases, a definitive therapeutic option for the disease has not yet been established. We herein report the case of a 57-year-old female patient with primary NEC of the breast who underwent a surgical resection and for whom the suitable adjuvant therapy is now being considered.
Matching Channels
Squamous cell carcinoma (SCC) is a carcinomatous cancer occurring in many different organs, including the skin, lips, mouth, esophagus, urinary bladder, prostate, lungs, vagina, and cervix. It is a...
Matching News
Global neuroendocrine carcinoma market to reach $475 million by 2019; report
The global Neuroendocrine carcinoma therapeutics market was worth $127 million in 2011 and now the market is forecast to increase at compound annual growth rate (CAGR) of 17.9% to reach $475 million b...
EC approves Afinitor for breast cancer
The European Commission approved Afinitor everolimus from Novartis AG (NYSE:NVS; SIX:NOVN) in combination with Aromasin exemestane to treat postmenopausal women with hormone receptor-positive, HER2-ne...
New Insight Into The Progression And Invasiveness Of The Most Common Type Of Breast Cancer
Ductal carcinoma in situ (DCIS) can be a predictor for invasive breast cancer if untreated, and is seen in around 45 percent of patients with invasive ductal carcinoma (IDC). Patients who only have D...
Recurrent patterns of genomic imbalances determine evolution of invasive breast cancer
Ductal carcinoma in situ (DCIS) is considered a precursor lesion for invasive breast cancer if untreated, and is found in approximately 45% of patients with invasive ductal carcinoma (IDC). Patients w...
Chemotherapy effective for patients with resected SCLC or large-cell neuroendocrine carcinoma
(International Association for the Study of Lung Cancer) Research presented in the July 2012 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology,...
New Light Shed On The Progression And Invasiveness Of Ductal Breast Cancer
Ductal carcinoma in situ (DCIS) is considered a precursor lesion for invasive breast cancer if untreated, and is found in approximately 45% of patients with invasive ductal carcinoma (IDC). Patients w...
Research presented in the July 2012 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology, concluded that patients with limited large cell neuroend...
FDA approves Afinitor for breast cancer
FDA approved Afinitor everolimus from Novartis AG (NYSE:NVS; SIX:NOVN) in combination with Aromasin exemestane to treat postmenopausal women with hormone receptor-positive, HER2-negative breast cancer...
Matching PubMed Articles
Bilateral primary breast neuroendocrine carcinoma in a young woman: Report of a case.
Bilateral breast carcinoma accounts for approximately 5% of all patients with breast cancer, while neuroendocrine breast carcinomas comprise less than 5% of invasive breast carcinomas. In addition, mo...
Primary pure neuroendocrine carcinoma of the breast is an extremely rare tumor. We report a case of primary solid neuroendocrine carcinoma in a 77-year-old postmenopausal woman who was admitted to the...
Primary neuroendocrine carcinoma of the breast: Report of a case.
Primary neuroendocrine carcinoma (NEC) of the breast appears to be a rare neoplasm. Due to the limited number of the cases, a definitive therapeutic option for the disease has not yet been established...
Solid papillary carcinoma, a special form of breast carcinoma with neuroendocrine differentiation, usually presents in women aged 60 years or more. (Koern, 2010). According to our best knowledge, we p...
Human achaete-scute homolog-1 expression in neuroendocrine breast carcinoma.
Neuroendocrine (NE) breast carcinoma is defined by morphological features similar to those of NE tumors of other organs and NE marker expression in at least 50 % of neoplastic cells. However, a NE mo...
